WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)

Saved in:
Bibliographic Details
Main Authors: Jonathon Barratt, Anant Desai, Alessia Fornoni, Lesley Inker, Irene de Lourdes Noronha, Alejandra Quevedo, Robert Shepherd, Alisha Smith, Hernan Trimarchi, Lucila Valente, Mona Wahba, Muh Geot Wong, Hiddo Lambers Heerspink
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924012476
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850223622408372224
author Jonathon Barratt
Anant Desai
Alessia Fornoni
Lesley Inker
Irene de Lourdes Noronha
Alejandra Quevedo
Robert Shepherd
Alisha Smith
Hernan Trimarchi
Lucila Valente
Mona Wahba
Muh Geot Wong
Hiddo Lambers Heerspink
author_facet Jonathon Barratt
Anant Desai
Alessia Fornoni
Lesley Inker
Irene de Lourdes Noronha
Alejandra Quevedo
Robert Shepherd
Alisha Smith
Hernan Trimarchi
Lucila Valente
Mona Wahba
Muh Geot Wong
Hiddo Lambers Heerspink
author_sort Jonathon Barratt
collection DOAJ
format Article
id doaj-art-a23b9121e4af4182a6e95f68ff9991c6
institution OA Journals
issn 2468-0249
language English
publishDate 2024-04-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-a23b9121e4af4182a6e95f68ff9991c62025-08-20T02:05:52ZengElsevierKidney International Reports2468-02492024-04-0194S550S55110.1016/j.ekir.2024.02.1158WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)Jonathon Barratt0Anant Desai1Alessia Fornoni2Lesley Inker3Irene de Lourdes Noronha4Alejandra Quevedo5Robert Shepherd6Alisha Smith7Hernan Trimarchi8Lucila Valente9Mona Wahba10Muh Geot Wong11Hiddo Lambers Heerspink12Dept Cardiovascular Sciences, University of Leicester, LeicesterNephrology, Amicis Research Centre, CaliforniaPeggy and Harold Katz Family Drug Discovery Center, University of Miami, MiamiKidney and Blood Pressure Center, Tufts University, BostonNephrology, Hospital das Clínicas da Faculdade de Medicina da USP, Sao PauloNephrology, Centro Medico Dra Maffei Investigación Clínica Aplicad, Buenos AiresBD, Dimerix Bioscience Pty Ltd, FitzroyClinical, Dimerix Bioscience Pty Ltd, FitzroyNephrology Dept, Hospital Britáinico de Buenos Aires, Buenos AiresNephrology Dept, Hospital das Clinicas da UFPE, RECIFENephrology Dept, St Heliers Hospital, LondonRenal Medicine, Concord Repatriation General Hospital, ConcordDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningenhttp://www.sciencedirect.com/science/article/pii/S2468024924012476
spellingShingle Jonathon Barratt
Anant Desai
Alessia Fornoni
Lesley Inker
Irene de Lourdes Noronha
Alejandra Quevedo
Robert Shepherd
Alisha Smith
Hernan Trimarchi
Lucila Valente
Mona Wahba
Muh Geot Wong
Hiddo Lambers Heerspink
WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
Kidney International Reports
title WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
title_full WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
title_fullStr WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
title_full_unstemmed WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
title_short WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
title_sort wcn24 1132 action3 phase 3 study of dmx 200 for the treatment of focal segmental glomerulosclerosis fsgs
url http://www.sciencedirect.com/science/article/pii/S2468024924012476
work_keys_str_mv AT jonathonbarratt wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT anantdesai wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT alessiafornoni wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT lesleyinker wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT irenedelourdesnoronha wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT alejandraquevedo wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT robertshepherd wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT alishasmith wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT hernantrimarchi wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT lucilavalente wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT monawahba wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT muhgeotwong wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs
AT hiddolambersheerspink wcn241132action3phase3studyofdmx200forthetreatmentoffocalsegmentalglomerulosclerosisfsgs